发明名称 |
RESPONSIVENESS TO ANGIOGENESIS INHIBITORS |
摘要 |
The invention is concerned with a method of determining whether a patient is more suitably treated by a therapy with an angiogenesis inhibitor, such as bevacizumab, by determing the genotype of VEGF promoter gene and/or VEGFR2 gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the treatment of a patient suffering from cancer based on the genotype of VEGF promoter gene and/or VEGFR2 gene. The invention further relates to a method for improving the treatment effect of chemotherapy of a patient suffering from cancer by adding an angiogenesis inhibitor, such as bevacizumab, based on the genotype of VEGF promoter gene and/or VEGFR2 gene. |
申请公布号 |
CA2845381(A1) |
申请公布日期 |
2013.03.07 |
申请号 |
CA20122845381 |
申请日期 |
2012.08.28 |
申请人 |
F. HOFFMANN-LA ROCHE AG;VIB VZW;LIFE SCIENCES RESEARCH PARTNERS VZW |
发明人 |
DE HAAS, SANNE LYSBET;DELMAR, PAUL;LAMBRECHTS, DIETHER;SCHERER, STEFAN |
分类号 |
C12Q1/68 |
主分类号 |
C12Q1/68 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|